Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Fund Type: Open-End Fund
  • Objective: Health Care Sector
  • Asset Class: Equity
  • Geographic Focus: Global

Adamant Global Biotech

+ Add to Watchlist

ADGLBII:SW

3,694.25 CHF 0.000.00%

As of 04:14:00 ET on 03/04/2015.

Snapshot for Adamant Global Biotech (ADGLBII)

Year To Date: +10.02% 3-Month: +10.90% 3-Year: +45.93% 52-Week Range: 2,114.38 - 3,694.25
1-Month: +15.10% 1-Year: +37.56% 5-Year: - Beta vs SMI: 1.16

Mutual Fund Chart for ADGLBII

No chart data available.
  • ADGLBII:SW 3,694.25
  • 1M
  • 1Y
Interactive ADGLBII Chart

Previous Close

No chart data available.
Interactive Chart
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Fund Profile & Information for ADGLBII

Adamant Global Biotech is an open-end fund incorporated in Switzerland. The objective of the Fund is to obtain long-term capital growth with active management. The Fund invests on a global basis in the shares of companies in the biotech sector.

Inception Date: 10-15-2010 Telephone: +41 800 850 050
Managers: JOHN MANIERI
Web Site: www.zkb.ch/fonds

Fundamentals for ADGLBII

NAV (on 2015-03-04) 3,694.25
Assets (M) (on 2015-03-04) 167.05
Fund Leveraged N
Minimum Investment 100,000.00
Minimum Subsequent Investment -

Dividends for ADGLBII

Dividend Type Omitted
Dividend Frequency Irreg
Last Dividend Net -
Dividend Yield (ttm) -

Fees & Expenses for ADGLBII

Front Load 1.20
Back Load 1.00
Current Mgmt Fee 1.20
Redemption Fee 1.00
12b1 Fee -
Expense Ratio 1.24

Top Fund Holdings for ADGLBII

Filing Date: 10/31/2014
Name Position Value % of Total
Amgen Inc 100,000 15,609,014 10.211%
Celgene Corp 145,000 14,944,972 9.776%
Gilead Sciences Inc 134,000 14,444,450 9.449%
Biogen Idec Inc 40,000 12,360,938 8.086%
Alexion Pharmaceuticals Inc 60,000 11,050,466 7.229%
Illumina Inc 43,000 7,969,991 5.214%
Vertex Pharmaceuticals Inc 73,000 7,913,957 5.177%
Mylan NV 140,000 7,215,488 4.720%
Regeneron Pharmaceuticals Inc 18,000 6,820,845 4.462%
Salix Pharmaceuticals Ltd 45,000 6,230,179 4.076%

Quotes delayed, except where indicated otherwise. Mutual fund NAVs include dividends. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil